Galectin Therapeutics(GALT) - 2025 Q3 - Quarterly Results

Exhibit 99.1 Galectin Therapeutics Reports Financial Results for the quarter ended September 30, 2025, and Provides Business Update NORCROSS, Ga., November 14, 2025 (GLOBE NEWSWIRE) – Galectin Therapeutics, Inc. (NASDAQ: GALT), the leading developer of therapeutics that target galectin proteins, today reported financial results and provided a business update for the three and nine months ended September 30, 2025. "The new NAVIGATE data presented at AASLD further strengthen the clinical and mechanistic profi ...